Tvardi Therapeutics (TVRD) Company Report

Analyst Earnings Quarterly Reports

Earnings summaries and quarterly performance for Tvardi Therapeutics.

Research analysts covering Tvardi Therapeutics.

Recent press releases and 8-K filings for TVRD.

Tvardi Therapeutics Provides Update on Clinical Programs and Financial Outlook

TVRD

New Projects/Investments

Guidance Update

Tvardi Therapeutics anticipates topline results from the TTI-101 Phase 2 HCC trial and Phase 1 healthy volunteer data for TTI-109 in 1H 2026.
Preliminary conclusions from the TTI-101 REVERTIPF study, released in October 2025, indicated that the placebo arm overperformed and treatment-emergent adverse events led to early discontinuations.
As of September 30, 2025, the company reported $36.5 million in cash, cash equivalents, and short-term investments, with an anticipated cash runway extending into Q4 2026.

Jan 16, 2026, 11:04 AM

Tvardi Therapeutics to Present New Phase 2 Clinical Trial Data at J.P. Morgan Healthcare Conference

TVRD

New Projects/Investments

Tvardi Therapeutics (TVRD) will deliver a company presentation at the 44th Annual J.P. Morgan Healthcare Conference on Thursday, January 15, 2026, at 12:00 PM PT.
The presentation will include a discussion and additional context regarding new Phase 2 REVERT IPF clinical trial data for TTI-101.
These new data demonstrate encouraging signals across fibrosis, inflammatory markers, and pulmonary function.

Jan 8, 2026, 9:05 PM

Tvardi Therapeutics Under Investigation Following Clinical Trial Disappointment

TVRD

Legal Proceedings

Faruqi & Faruqi, LLP is investigating potential claims against Tvardi Therapeutics (TVRD) on behalf of investors.
Tvardi's shares plummeted over 80% on Monday, October 13, 2025, after the company released disappointing preliminary data from its Phase 2 REVERT clinical trial of TTI-101 for idiopathic pulmonary fibrosis.
The company concluded that the study did not meet its goals after reviewing preliminary safety and exploratory efficacy results, including changes in Forced Vital Capacity (FVC).

Dec 21, 2025, 3:11 PM

Tvardi Therapeutics, Inc. Provides Corporate Presentation with Clinical and Financial Updates

TVRD

New Projects/Investments

Guidance Update

Tvardi Therapeutics, Inc. published an updated corporate presentation on November 19, 2025, detailing clinical progress and financial status.
The company anticipates topline data in 1H 2026 for its TTI-101 Phase 1b/2 trial in Hepatocellular Carcinoma (HCC), with interim data showing a 92% Disease Control Rate (DCR) and 33% Objective Response Rate (ORR) in Cohort C.
Phase 1 healthy volunteer data for TTI-109 is also expected in 1H 2026, following its Investigational New Drug (IND) filing in June 2025.
As of September 30, 2025, the company held $36.5 million in cash, cash equivalents, and short-term investments, projecting a cash runway into Q4 2026.

Nov 19, 2025, 11:44 AM

Tvardi Therapeutics Announces Third Quarter 2025 Results and Business Update

TVRD

Earnings

Guidance Update

New Projects/Investments

Tvardi Therapeutics reported a net loss of $5.5 million and a basic and diluted net loss per share of $0.59 for the third quarter ended September 30, 2025.
As of September 30, 2025, the company held $36.5 million in cash, cash equivalents, and short-term investments, with a cash runway anticipated to fund operations into Q4 2026.
The company expects topline data from its Phase 2 trial of TTI-101 in hepatocellular carcinoma (HCC) and results from a healthy volunteer study of its next-generation STAT3 inhibitor, TTI-109, in H1 2026.
Preliminary data from the Phase 2 REVERT IPF trial did not meet its goals.

Nov 13, 2025, 9:14 PM

Tvardi Therapeutics Provides Update on Preliminary Phase 2 REVERT Trial Data

TVRD

Tvardi Therapeutics, Inc. announced that its Phase 2 REVERT clinical trial of TTI-101 in idiopathic pulmonary fibrosis (IPF) did not meet its goals, with preliminary data showing no statistically significant differences in exploratory efficacy between treatment arms and placebo.
The trial experienced high discontinuation rates in the TTI-101 treated arms (56.7% for 400mg and 62.1% for 800mg) compared to placebo (10.3%), primarily due to gastrointestinal adverse events.
Tvardi remains on track to report preliminary topline data in the first half of 2026 for a healthy volunteer study of TTI-109 and a Phase 2 trial of TTI-101 in hepatocellular carcinoma.
As of June 30, 2025, the company reported $41.0 million in cash, cash equivalents, and short-term investments, which is expected to fund operations into the fourth quarter of 2026.